- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02977572
Non-invasive Ventilation Versus Continuous Positive Airway Pressure in Cardiogenic Pulmonary Edema
Non-Invasive Mechanical Ventilation Versus Continuous Positive Airway Pressure Relating to Cardiogenic Pulmonary Edema in an Intensive Care Unit
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Continuous Positive Airway Pressure (CPAP) and Non-Invasive Ventilation (NIV), has played a decisive role in the treatment of Acute Respiratory Failure (ARF) secondary to Cardiogenic Pulmonary Edema (CPE). The use of either CPAP or NIV has resulted in greater clinical improvements than the ones that have been previously obtained by using a standard medical therapy. Although there is a strong indication for NIV in hypercapnic patients, the situation whether NIV is superior to CPAP remains unclear, and hence, both have been recommended.
NIV and CPAP have both been successfully used in patients admitted to an Intensive Care Unit (ICU) suffering from CPE. However, few trials have been published on the ICU scenario. In addition, Acute Coronary Syndrome (ACS) has been considered to be an exclusion criterion in several trials.
At the time of the onset of CPE, either in the Emergency Department (ED) or in the ward, all participants received a standard medical therapy (oxygen through a Venturi mask, morphine, intravenous nitroglycerin if their systolic blood pressure >160 mmHg, together with loop diuretics), all at the discretion of the attending physician. In the absence of a clinical improvement [dyspnea, respiratory rate >25rpm, transcutaneous arterial oxygen saturation (SaO2) <90%], the participant was admitted to the ICU and assigned to the NIV group or the CPAP group, regardless of the treatment that they had received in the ED. The participants that were admitted to the ICU at the onset of CPE were randomised without a trial of medical treatment. The assignment of each group was performed by opening a sealed envelope following a prior randomisation by using a computerised system.
Statistical. A comparative analysis was conducted by using the Student's t-test or the Mann-Whitney test for a comparison of the quantitative variables for the parametric and non-parametric characteristics, respectively. For the qualitative variables, the investigators used the Chi-Square statistic or Fisher's exact test. A statistical significance was reached if P<0.05. The cumulative probability of survival was compared by using a Kaplan-Meier estimation of survival and a Log-Rank Test to compare both of the groups.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants suffering from CPE, defined as having the presence of dyspnea, respiratory rate >25 breaths/minute, the use of accessory respiratory muscles, cyanosis, cold sweats, bilateral crackles and/or wheezing on pulmonary auscultation, hypoxaemia, hypertension, and a predominance of bilateral pulmonary infiltrates upon a chest radiography (if available).
- The potential causes of CPE have been understood to be Acute Coronary Syndrome (ACS) with or without a persistent ST-segment elevation, hypertensive emergency, valvulopathy, acute arrhythmia, endocarditis, or decompensation due to a chronic heart failure.
Exclusion Criteria:
- The exclusion criteria were: a refused consent, the patient's inability to cooperate, severe encephalopathy (Glasgow Coma Score <10)
- Anatomical difficulty when adjusting the face mask, non-cardiogenic Acute Respiratory Failure (pneumonia, blunt chest trauma, or chronic obstructive pulmonary disease)
- Respiratory or cardiac arrest on admission, together with the need for an immediate intubation.
- Specific cardiac contraindications were also considered, including: cardiogenic shock on admission established by systolic blood pressure (SBP) <90 mmHg, or a dependence on vasoactive drugs (norepinephrine >0.5 µg/kg/min).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Non-Invasive ventilation (NIV group)
For the NIV group, a BiPAP Vision was used, by setting the Inspiratory Positive Airway Pressure (IPAP) at a level that was required to achieve a tidal volume of approximately 8-10 ml/kg.
Also an Expiratory Positive Airway Pressure (EPAP) was set at a minimum of 5 cmH20 during the first hour, gradually increasing until there was a clinical improvement.
Fraction inspiratory of oxygen (FiO2) was applied to maintain a transcutaneous arterial oxygen saturation (SaO2) of 92%-94%.
NIV was continuously applied until there was a clinical and/or a gasometrical improvement, at which time they were replaced by a Venturi mask with FiO2 of 0.4.
|
In arm description
|
Placebo Comparator: Continuous Positive AirwayPressure CPAP
The CPAP was applied by using a flow generator with adjustable fractional inspired oxygen (FiO2).
This was connected to the Positive End-Expiratory Pressure (PEEP) valve that was placed in the face mask.
In the second instance, the CPAP system that was used was a Boussignac CPAP System Flow Jet.
The Boussignac valve takes gas from a single source and splits it in order to create four high flow jets.
These jets converge in the chamber creating a virtual valve.
A initial level of 5cmH20 of PEEP was recommended for the first hour of ventilation, with subsequent increments (up to 15cmH20) until a clinical improvement was obtained.
CPAP was continuously applied until there was a clinical and/or a gasometrical improvement, at which time it was replaced by a Venturi mask.
|
In arm description
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Need for an Endotracheal Intubation Within Seven Days After Onset of Cardiopulmonary Edema at the Intensive Care Unit
Time Frame: Whitin seven days after onset of cardiopulmonary edema at the Intensive Care Unit
|
Whitin seven days after onset of cardiopulmonary edema at the Intensive Care Unit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of the Ventilation
Time Frame: Time (hours) from start of ventilation until the removal of both devices because of improve or failure
|
Period of ventilation (either noninvasive ventilation or continouos positive airway pressure) while the patient suffers from acute respiratory failure secondary to cardiopulmonary edema
|
Time (hours) from start of ventilation until the removal of both devices because of improve or failure
|
Ventilator Acquired Pneumonia
Time Frame: Pulmonary infection at intensive care unit diagnosed until 72 hours after removal of ventilation
|
Pulmonary infections (%) during stay at intensive care unit
|
Pulmonary infection at intensive care unit diagnosed until 72 hours after removal of ventilation
|
Acute Renal Failure
Time Frame: Acute Renal Failure during intensive care unit stay (at discharge from intensive care unit)
|
Development of acute renal failure measured as increase of level of creatinine
|
Acute Renal Failure during intensive care unit stay (at discharge from intensive care unit)
|
Length of Stay at Intensive Care Unit
Time Frame: Length of stay (days) at Intensive Care Unit at discharge from intensive care unit.
|
Length of stay of the patient at Intensive Care Unit
|
Length of stay (days) at Intensive Care Unit at discharge from intensive care unit.
|
Length of Hospital Stay
Time Frame: Length of stay (days) at hospital at discharge from hospital
|
All the time (days) the patient stays at the hospital
|
Length of stay (days) at hospital at discharge from hospital
|
Intensive Care Unit Mortality
Time Frame: Mortality (%) at Intensive Care Unit at discharge from intensive care unit
|
Mortality (%) at Intensive Care Unit
|
Mortality (%) at Intensive Care Unit at discharge from intensive care unit
|
28th Day Mortality
Time Frame: Mortality within 28 days of randomization
|
Mortility of patients within of the first 28 days after randomization (either at intensive car unit or at hospital)
|
Mortality within 28 days of randomization
|
Hospital Mortality
Time Frame: Mortality (%) at Hospital at discharge from hospital
|
Mortality during hospital stay (including at Intensive care mortality)
|
Mortality (%) at Hospital at discharge from hospital
|
Collaborators and Investigators
Investigators
- Principal Investigator: ALBERTO BELENGUER-MUNCHARAZ, MD, INTENSIVE CARE UNIT. HOSPITAL GENERAL CASTELLO
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HGU Castellon-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiogenic Pulmonary Oedema
-
Cliniques universitaires Saint-Luc- Université...Frederic Thys,MD,PhDWithdrawnARF Secondary to COPD Exacerbation | ARF Secondary to Cardiogenic Acute Pulmonary OedemaBelgium
-
GlaxoSmithKlineCompleted
-
University of MonastirCompleted
-
Hopital LariboisièreCompleted
-
National University of Ireland, Galway, IrelandMerlin Park University Hospital, Galway, IrelandUnknown
-
University Hospital, ToulouseCompleted
-
University Hospital, Strasbourg, FranceRecruitingCardiogenic Pulmonary EdemaFrance
-
Hospital Raja Permaisuri BainunCompletedAcute Cardiogenic Pulmonary Edema
-
Beijing Chao Yang HospitalCompletedAcute Cardiogenic Pulmonary EdemaChina
-
Assiut UniversityCompletedAcute Cardiogenic Pulmonary EdemaEgypt
Clinical Trials on Non-Invasive Ventilation
-
Guy's and St Thomas' NHS Foundation TrustCompletedMotor Neurone Disease | Hypoxemia and/or HypercapniaUnited Kingdom
-
Centre Chirurgical Marie LannelongueCentre Hospitalier René Dubos; University Hospital, Bordeaux; University Hospital... and other collaboratorsCompletedRespiratory InsufficiencyFrance
-
Hamilton Health Sciences CorporationRecruiting
-
Universidade Federal do Rio Grande do NorteCompletedChronic Obstructive Pulmonary DiseaseBrazil
-
Spaulding Rehabilitation HospitalCompletedSpinal Cord InjuryUnited States
-
University Hospital, MontpellierCompletedRespiratory Failure | Non Invasive Ventilation on Healthy VolunteerFrance
-
Sociedad Española de Neumología y Cirugía TorácicaCompletedObesity Hypoventilation Syndrome | Chronic Hypercapnic Respiratory FailureSpain
-
Postgraduate Institute of Medical Education and...Completed
-
Centre Hospitalier Intercommunal de Toulon La Seyne...Completed
-
Azienda Ospedaliera SS. Antonio e Biagio e Cesare...RecruitingAcute Respiratory FailureItaly